2-(4-溴苯基)-1,3-噻唑-4-甲酸 | 21160-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-溴苯基)-1,3-噻唑-4-甲酸
• 中文别名: 2-(4-溴苯基)-4-噻唑羧酸
• 英文名称: 2-(4-bromophenyl)-1,3-thiazole-4-carboxylic acid
• 英文别名: 2-(4-bromophenyl)thiazole-4-carboxylic acid；2-p-Brom-phenyl-thiazol-4-carbonsaeure；2-(4'-Bromphenyl)-4-carboxy-thiazol
• CAS: 21160-50-9
• 化学式: C₁₀H₆BrNO₂S
• 分子量: 284.133
• InChiKey: FSXGZVXOAJEGDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934100090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(4-Bromophenyl)thiazole-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(4-Bromophenyl)thiazole-4-carboxylic acid
CAS number: 21160-50-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H6BrNO2S
Molecular weight: 284.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-溴苯基)-1,3-噻唑-4-甲酸 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 1-[2-(4-溴-苯基)-噻唑-4-基]-乙酮
  参考文献：
  名称：

  Rh(iii)-catalyzed cyclization reaction of azoles with alkynes: efficient synthesis of azole-fused-pyridines

  摘要：

  已开发出一种Rh（III）催化的氮杂环与炔烃的环化反应，可在良好至优异的产率下构建杂环并联吡啶。

  DOI：

  10.1039/c5ob01338k
• 作为产物：
  描述：

  2-(4-溴苯基)-噻唑-4-甲醛 生成 2-(4-溴苯基)-1,3-噻唑-4-甲酸
  参考文献：
  名称：

  Simiti,I.; Farkas,M., Bulletin de la Societe Chimique de France, 1968, p. 3862 - 3866

  摘要：

  DOI：

文献信息

• FAP 저해제로서의 피롤리딘 유도체 및 이를 포함하는 약학적 조성물
  申请人：Boryung Corporation 주식회사 보령(119980015994) Corp. No ▼ 110111-0012560BRN ▼208-81-00281

  公开号：KR20200115934A

  公开（公告）日：2020-10-08

  본 발명은 FAP 저해제로서 하기 화학식 X로 나타내는, 피롤리딘 유도체 또는 그의 약학적으로 허용되는 염을 포함한다. [화학식 X]

  本发明涉及一种FAP抑制剂，包括用化学式X表示的吡啶衍生物或其药学上可接受的盐。 [化学式 X]
• Die Anwendung der Sommelet-Reaktion bei 2-Aryl-4-chlormethyl-5-brom-thiazolen Beiträge zum Studium einiger Heterocyclen XXXI
  作者：I. Simiti、Maria Farkas

  DOI：10.1002/ardp.19743070202

  日期：——

  Das Verhalten von 2‐Aryl‐4‐chlormethyl‐5‐brom‐thiazolen unter den Bedingungen der direkten und indirekten Sommelet‐Reaktion wird beschrieben.

  描述了 2-芳基-4-氯甲基-5-溴噻唑在直接和间接 Sommelet 反应条件下的行为。
• [EN] NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ANTAGONISTES SÉLECTIFS DU RÉCEPTEUR NK-3, COMPOSITION PHARMACEUTIQUE ET MÉTHODES POUR UNE UTILISATION DANS DES TROUBLES À MÉDIATION PAR DES RÉCEPTEURS NK-3
  申请人：EUROSCREEN SA

  公开号：WO2011121137A1

  公开（公告）日：2011-10-06

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及公式I的新化合物及其作为治疗化合物的用途。
• NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS
  申请人：Euroscreen S.A.

  公开号：US20130023530A1

  公开（公告）日：2013-01-24

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及一种新型化合物I的使用作为治疗化合物。
• NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
  申请人：Ogeda SA

  公开号：US10065960B2

  公开（公告）日：2018-09-04

  The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

  本发明涉及式 I 的新型化合物 及其作为治疗化合物的用途。